| abstract |
The present invention involves the construction of a recombinant expression vector involving combination of an IgG antibody Fc domain gene in a receptive domain gene of the extracellular region of DLK1, and the expression and purification of DLK1-Fc fusion protein in 293E cells, and the DLK1-Fc fusion protein has been confirmed to markedly reduce cancer cell migration and to be efficacious as a drug for a concept for practical cancer metastasis suppression through pharmacokinetic parameter calculation. The present invention can be used advantageously as an active ingredient in a composition for inhibiting cancer metastasis since DLK1-Fc fusion protein is more stable than non-fusion protein, markedly reduces migration in various cancer cell strains, and has an outstanding metastasis-inhibiting effect even at low concentration. |